UroGen Pharma Ltd.
Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $29.87
- 52-Week Range
- $16.50 – $50.81
- Market Cap
- $1.46B
- P/E (TTM)
- —
- EPS (TTM)
- -1.31
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- —
- PEG Ratio
- —
- Return on Equity
- —
- Return on Assets
- -8.46%
- Gross Margin
- 91.41%
- Operating Margin
- -12.36%
- Profit Margin
- -26.27%
- Current Ratio
- 3.40
- Debt/Equity
- —
- Total Debt
- $196.28M
- Free Cash Flow
- $-97.18M
- Revenue Growth
- 223.90%
- Earnings Growth
- —
- Enterprise Value
- $1.57B
Market Snapshot
About
UroGen Pharma is a biopharmaceutical company developing treatments for urological cancers and diseases. The company specializes in RTGel technology, a proprietary sustained-release hydrogel formulation that enables prolonged exposure of urological tissues to therapeutic agents. UroGen focuses on bladder and upper urinary tract cancers.